EntryPoint Capital LLC Invests $472,000 in MiMedx Group, Inc. (NASDAQ:MDXG)

EntryPoint Capital LLC acquired a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 49,093 shares of the company’s stock, valued at approximately $472,000.

A number of other institutional investors and hedge funds have also bought and sold shares of MDXG. IMG Wealth Management Inc. bought a new position in shares of MiMedx Group in the fourth quarter worth approximately $28,000. Van ECK Associates Corp purchased a new position in MiMedx Group in the 4th quarter worth approximately $40,000. Point72 DIFC Ltd lifted its position in MiMedx Group by 127.6% in the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after acquiring an additional 4,275 shares in the last quarter. AlphaQuest LLC purchased a new stake in MiMedx Group during the 4th quarter valued at $88,000. Finally, Koss Olinger Consulting LLC bought a new stake in shares of MiMedx Group in the 4th quarter worth $100,000. 79.15% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CAO William Frank Iv Hulse sold 81,446 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the sale, the chief accounting officer now owns 494,774 shares of the company’s stock, valued at $3,859,237.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. This represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 144,018 shares of company stock valued at $1,130,312. Insiders own 1.30% of the company’s stock.

MiMedx Group Stock Down 2.5 %

Shares of MiMedx Group stock opened at $7.90 on Wednesday. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 14.36 and a beta of 1.97. The company’s 50 day moving average is $8.35 and its 200 day moving average is $7.89.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. Research analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.